Exact Sciences (EXAS) Tops Q3 EPS by 5c; Raises FY Rev Outlook

Exact Sciences (NASDAQ: EXAS) reported Q3 EPS of ($0.37), $0.05 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $118.3 million versus the consensus estimate of $109.31 million.

GUIDANCE:

Exact Sciences sees FY2018 revenue of $435-440 million, versus prior of $420-$430 million and the consensus of $428.75 million.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• After-Hours Stock Movers: FDX, CBRS, NKE